Carmine N. Stengone insider trades

Open-market stock purchases and sales by Carmine N. Stengone, Director at Kiora Pharmaceuticals Inc, from SEC Form 4 filings since Sep 29, 2023.

Track record: 0% of 1 scored buy are up 5% or more since purchase, averaging -25%.

Recent trades

DateStockTradeValue
Jun 10, 2026KPRX Kiora Pharmaceuticals IncBought (not open market)—
Feb 25, 2026CTNM Contineum Therapeutics, IncBought (not open market)—
Feb 25, 2026CTNM Contineum Therapeutics, IncSold$43.2K
Feb 24, 2026CTNM Contineum Therapeutics, IncBought (not open market)—
Feb 24, 2026CTNM Contineum Therapeutics, IncSold$70.5K
Feb 11, 2026CTNM Contineum Therapeutics, IncSold$6.4K
Feb 11, 2026CTNM Contineum Therapeutics, IncBought (not open market)—
Jan 30, 2026CTNM Contineum Therapeutics, IncBought (not open market)—

Companies traded

  • KPRX Kiora Pharmaceuticals Inc: 1 buy, last Jun 10, 2026
  • CTNM Contineum Therapeutics, Inc: 3 sales, last Feb 25, 2026

Get free alerts when Carmine N. Stengone files a new trade →